1OLSCHEWSKI H,ARDESCHIR GH,SCHMEHL T,et al.Inhaled iloprost to treat severe pulmonary hypertension:an uncontrolled trial[J].Ann Intern Med,2000,132 (6):435-443.
2GHOFRANI HA,WIEDEMANN R,ROSE F,et al.Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension[J].Ann Intern Med,2002,136 (7):515-522.
4Bando K,Turrentine M W,Sharp T G,et al.Pulmonary Hypertension after Operations for Congenital Heart Diseases:Analysis of Risk Factors and Management[J].J Thorac Cardiovasc Surg,1996,112(6):1600-1609.
5Roberts J D Jr,Lang P,Bigatello L M,et al.Inhaled Nitric Oxide in Congenital Heart Disease[J].Circulation,1993,87(2):447-453
6Birukova AA, Zagranichnaya T, Fu P, et al. Prostaglandins PGE2 and PGI2 promote endothelial barrier enhancement via PKA-and Epacl/Rapl-dependent Rac activation. Exp Cell Res, 2007,313(11): 2504-2520.
7Hashimoto N, Takeyoshi I, Yoshinari D, et al. Effects of a p38 mitogen-activated protein kinase inhibitor as an additive to Euro-Collins solution on reperfusion injury in canine lung transplantation1. Transplantation, 2002, 74(3): 320-326.
8Grimminger F, Rose F, Ghofrani HA, et al. Inhalative strate- gies for improvement of pulmonary hemodynamics and gas ex- change in sepsis and severe pulmonary hypertension. Z Kardi- ol, 2000, 89(6): 477-484.
9Dembinski R, Brackhahn W, Henzler D, et al. Cardiopulmo- nary effects of iloprost in experimental acute lung injury. Eur Respir .1, 2005, 25(1): 81-87.
10Birukova AA, Wu T, Tian Y, et al. Iloprost improves endo- thelial barrier function in iipopolysaccharide-induced lung inju- ry. Eur Respir J, 2013, 41(1): 165-176.
